Home Online Features Hengrui's Camrelizumab Combo Therapy Doubles the Five -Year Survival of Patients with Advanced Squamous Lung Cancer - A Potential Paradigm Shift in Clinical Outcome for this Difficult-to Treat Population
Hengrui’s Camrelizumab Combo Therapy Doubles the Five -Year Survival of Patients with Advanced Squamous Lung Cancer – A Potential Paradigm Shift in Clinical Outcome for this Difficult-to Treat Population
Press Releases
April 1, 2025

Hengrui’s Camrelizumab Combo Therapy Doubles the Five -Year Survival of Patients with Advanced Squamous Lung Cancer – A Potential Paradigm Shift in Clinical Outcome for this Difficult-to Treat Population

By Hengrui Pharmaceuticals

PARIS, April 1, 2025 /PRNewswire/ -- At the European Lung Cancer Congress 2025 (ELCC) (Paris, France, March 26 to 29), Hengrui Pharmaceuticals presented the 5-year long-term follow-up data from the

bradford

The Bradford Era

email
Local & Social